Global Kras Inhibitors Market Driven By Increasing Kras Mutation Rates
The Kras inhibitors market comprises drugs that specifically target mutations in the KRAS gene, which is one of the most common driver mutations found in various cancers like lung cancer and colorectal cancer. KRAS mutations are found in around 25% of all cancers and have traditionally proven difficult to directly target with existing drugs. However, recent breakthroughs in understanding the structure and function of mutated KRAS have enabled the development of several Kras inhibitors. These drugs have the potential to effectively treat KRAS-driven cancers and improve clinical outcomes for patients.
The Global Kras Inhibitors Market is estimated to be valued at USD 104.5 Mn in 2024 and is expected to reach USD 146.6 Mn by 2031, growing at a compound annual growth rate (CAGR) of 4.98% from 2024 to 2031.
The current geopolitical tensions are impacting the growth of the global KRAS inhibitors market. With rising political instability and conflicts in different parts of the world, international trade and collaborations have been affected. This is hindering the supply chain and distribution channels of Global Kras Inhibitors Market.
Get More Insights On- Global Kras Inhibitors Market
Get This Report in Japanese Language: 世界のKras阻害剤市場
Get This Report in Korean Language: 글로벌 크라스 억제제 시장
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian